"IP" paid through the actual products produced by immutep...

"IP" paid through the actual products produced by immutep (WuXi).. immutep is developing a product line as a treatment method/system.. there are many treatment regimes that do involve several different products patented by different companies.. (HIV treatments).. MV has done the marketing, that is why immutep actually has a chance of becoming the go-to for immuno therapeutics.. FreedyT was too slow to develop Lag-3 when he was given the sole rights too... lucky we have a great team behind him now.. no man is an island..

@ahjay "What is to stop Immutep becoming a commercial entity solely aimed at satisfying big pharmas
research requirements in combination therapies in immuno-oncology sector re lag-3 gene....
Any particular research aimed at different indications etc....
Lag-3 IP remains in immutep hands and big pharma commission trials with the funding/payment
to be negotiated?"

IMO nothing mate... I actually think that is where the management are heading.... through both licensing and standalone product development...

Immutep is quite capable of being a stand alone company leading the biotech industry in Lag-3 (who knows what else)...

If immutep does rapidly develop a revenue stream, it can quickly take the lead in autoimmune diseases (2 more cap raises could accelerate progress).... cancer is the proving ground for safety and efficacy... the top 100 list,https://www.aarda.org/diseaselist/. the conditions on this list and the ones that have not made the top 100 cost society a lot more in health care and lost lives of productive capacity... as mentioned by FreddyT in his interview, diabetes... just one of the top 100.. learn what is on the list, arthritis another..

remember MV has set up testing, manufacturing and distribution networks through strategic partnerships developed over his tenure... bloody great CEO...

mRNA is currently under going the biggest human trials ever undertaken... (covid)...
someone knows a fair bit about it..
Back in 1988, I was working at Institut Gustave Roussy, south of Paris and cloned mRNA specifically expressed in human T cells after their,,